One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Repligen Corporation logo
Repligen Corporation RGEN
$ 163.68 -3.99%
report update icon

Quarterly report 2026-Q3
added 10-30-2026

Repligen Corporation Financial Statements 2025-2009 | RGEN

Annual Financial Statements Repligen Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

6.67 B 8.41 B 10.8 B 9.54 B 14.6 B 10.1 B 4.91 B 2.44 B 1.37 B 970 M 728 M 789 M 501 M 213 M 123 M 102 M -

Shares

56.2 M 55.9 M 55.7 M 55.5 M 55 M 52.6 M 48.3 M 43.8 M 38.2 M 33.6 M 32.9 M 32.5 M 31.7 M 30.9 M 30.8 M 30.8 M -

Historical Prices

119 150 193 172 265 192 92.5 52.7 36.3 30.8 28.3 19.8 13.6 6.28 3.47 3.33 4.37

Net Income

48.9 M -25.5 M 35.6 M 186 M 128 M 59.9 M 21.4 M 16.6 M 28.4 M 11.7 M 9.34 M 8.17 M 16.1 M 14.2 M -43.5 K 1.99 M -

Revenue

738 M 634 M 632 M 802 M 671 M 366 M 270 M 194 M 141 M 105 M 83.5 M 63.5 M 68.2 M 62.3 M 27.3 M 21.4 M -

Cost of Revenue

352 M 360 M 354 M 346 M 279 M 157 M 119 M 86.5 M 67 M 47.1 M - - - - - - -

Gross Profit

386 M 275 M 278 M 456 M 391 M 60.5 M 151 M 108 M 74.2 M 57.4 M 48.3 M 35.5 M 43 M 35.1 M 20.2 M - -

Operating Income

55.2 M -35.1 M 47.7 M 225 M 167 M 69.8 M 36.1 M 26 M 14 M 16 M 13.8 M 10.7 M 22.9 M 11.1 M -374 K 1.71 M -

Interest Expense

2.82 M -5.17 M 1.95 M 1.16 M 11.3 M 10.8 M 9.29 M 6.71 M 6.44 M 3.77 M 32 K 50 K 50 K 56.7 K 26.2 K 12.7 K -

EBITDA

134 M 34.6 M 116 M 276 M 206 M 96.9 M 57 M 41.8 M 24.5 M 24.6 M 22.4 M 16.8 M 26.1 M 14.9 M 1.3 M 2.99 M -

Operating Expenses

331 M 310 M 231 M 231 M 224 M 91.2 M 115 M 81.5 M 60.2 M 38.2 M 30.4 M 22.8 M 20 M 23.7 M 20.5 M - -

General and Administrative Expenses

291 M 263 M 219 M 216 M 184 M 120 M 95.6 M 65.7 M 51.5 M 30.9 M 24.7 M 17.2 M 12.7 M 13.2 M 8.02 M 5.58 M -

All numbers in USD currency

Quarterly Income Statement Repligen Corporation

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

56.6 M 56.4 M 56.4 M -56.2 M 56.3 M 56.2 M 56.1 M 41 M 56 M 55.9 M 55.8 M 32 M 55.8 M 55.7 M 55.6 M 28 M 55.5 M 55.4 M 55.4 M 97 55 M 54.9 M 54.8 M 54.8 M 52.5 M 52.4 M 52.1 M 1.26 M 50.9 M 46.4 M 44 M 43.7 M 43.8 M 43.7 M 43.6 M 43.6 M 41.2 M 34.1 M 33.9 M 33.8 M 33.8 M 33.6 M 33 M 32.9 M 32.9 M 32.9 M 32.8 M 32.7 M 32.7 M 32.2 M 32 M 31.9 M 31.9 M 31.6 M 31.2 M 31.1 M 30.9 M 30.8 M 30.7 M 30.7 M 30.8 M 30.8 M 30.8 M

Net Income

-38.4 M 5.01 M 8.33 M 13.3 M 14.9 M 14.9 M 5.83 M -33.9 M -654 K 5.71 M 3.3 M -16.4 M 16.9 M 19.8 M 15.3 M 48.7 M 40.4 M 49.9 M 47 M 29.1 M 33.5 M 36.2 M 29.4 M 19.7 M 14.6 M 15.9 M 9.82 M 3.6 M 1.66 M 8.1 M 8.05 M 5.64 M 4.79 M 2.74 M 3.45 M 12.2 M 4.67 M 8.44 M 3.07 M 5.03 M 1.16 M 3.87 M 1.62 M 265 K 2.54 M 3.61 M 2.93 M -398 K 1.47 M 2.82 M 4.28 M 3.33 M 5.89 M 4.54 M 2.34 M 9.55 M 1.81 M 1.57 M 1.23 M -2.16 M 605 K -55 K -2.03 M

Revenue

209 M 204 M 194 M 198 M 189 M 182 M 169 M 168 M 155 M 159 M 153 M 167 M 141 M 159 M 165 M 187 M 201 M 208 M 206 M 187 M 178 M 163 M 143 M 109 M 94.1 M 87.5 M 76.1 M 69.5 M 69.4 M 70.7 M 60.6 M 51.9 M 49.5 M 47.7 M 44.8 M 41.6 M 36.6 M 32.5 M 30.6 M 25.6 M 24.7 M 29.2 M 25.1 M 21.4 M 19.8 M 21.5 M 20.8 M 16.4 M 15.3 M 15.6 M 16.3 M 15.4 M 18.8 M 17.5 M 16.5 M 18.8 M 15.1 M 15.5 M 12.8 M 7.16 M 8.63 M 7.65 M 5.91 M

Cost of Revenue

98.3 M 94.1 M 86 M 96.5 M 88.3 M 89.4 M 77.8 M 129 M 77.4 M 77.3 M 76.4 M 88.1 M 105 M 79.3 M 81.8 M 90.7 M 86.5 M 86.3 M 82.4 M 82 M 75.5 M 62 M 59.7 M - 39.6 M 36.9 M 32 M 30.1 M 31.4 M 30.7 M 26.8 M 23.6 M 22.2 M 21.1 M 19.7 M - 20 M 13.9 M - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

111 M 110 M 108 M 101 M 101 M 93 M 91.4 M 38.8 M 77.5 M 81.5 M 76.8 M 78.5 M 36.6 M 79.9 M 83.5 M 96.1 M 114 M 121 M 124 M 104 M 103 M 101 M 83.1 M 60.5 M 54.4 M 50.6 M 44.1 M 39.4 M 38 M 40 M 33.8 M 28.4 M 27.3 M 26.6 M 25.2 M 22.5 M 16.6 M 18.5 M 16.6 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-29.5 M 14 M 15.9 M 17.9 M 16.8 M 13.9 M 6.58 M -36.5 M -7.83 M 5.47 M 3.75 M 9.87 M 4.69 M 19.3 M 13.9 M 48.8 M 52.7 M 63.2 M 60 M 37.4 M 45.2 M 48.2 M 36.4 M - 21 M 19.5 M 11.9 M 5.89 M 7.96 M 11.1 M 11.2 M 7.85 M 7.89 M 4.27 M 5.98 M 3.26 M -406 K 5.47 M 5.68 M 2.9 M 3.75 M 5.86 M 3.46 M 1.43 M 3.69 M 4.61 M 4.04 M 61 K 2.22 M 3.11 M 5.31 M 5.18 M 8.04 M 6.1 M 3.54 M 6.41 M 2.19 M 1.32 M 1.17 M -1.54 M 552 K -121 K -2.09 M

Interest Expense

1.91 M -273 K -750 K 403 K -804 K 3.5 M -286 K -4.53 M 3.1 M -215 K -3.54 M 6.62 M 895 K 528 K 77 K 858 K -6.59 M -3.4 M -402 K 621 K -786 K -779 K -224 K - 3.05 M 3 M 2.98 M -291 K 316 K -697 K 358 K 75 K -134 K 251 K 71 K -139 K 1.62 M 1.6 M 1.58 M 119 K 1.56 M 638 K 5 K -270 K 8 K 8 K 9 K -12 K 11 K 13 K 14 K -12 K 11.7 K 12.4 K 13.5 K -14 K -7 K 27.4 K 22.4 K 28 K 13.5 K 13.5 K 13 K

EBITDA

-19.9 M 23.5 M 25.7 M 27.7 M 26.7 M 24.2 M 15.7 M -27.8 M 768 K 14.2 M 12.4 M 18.7 M 12.3 M 27 M 21.3 M 56.1 M 59.3 M 69.8 M 66.6 M 43.4 M 50.9 M 53.4 M 41.6 M - 40.5 M 32.4 M 18.3 M 9.89 M 11.9 M 14.2 M 13.8 M 10.6 M 10.5 M 6.87 M 8.68 M 3.26 M 5.97 M 8.75 M 7.26 M 2.9 M 7.59 M 8.32 M 4.61 M 1.43 M 7.14 M 6.9 M 5.19 M 61 K 5.18 M 4.96 M 6.2 M 5.18 M 10.3 M 7.61 M 4.36 M 6.41 M 4.78 M 3.01 M 1.99 M -1.54 M 1.76 M 285 K -1.69 M

Operating Expenses

141 M 96.1 M 92.3 M 83.5 M 83.7 M 79.1 M 84.8 M 75.3 M 85.3 M 76.1 M 73 M 68.6 M 31.9 M 60.6 M 69.7 M 47.2 M 61.6 M 58.2 M 64 M 67 M 57.5 M 52.7 M 46.7 M 91.2 M 73.1 M 67.9 M 64.2 M 63.6 M 61.5 M 59.6 M 49.5 M 44.1 M 41.6 M 43.5 M 38.9 M 38.3 M 37 M 27 M 24.9 M -2.9 M - - - -1.43 M - - - -61 K - - - -5.18 M - - - -6.41 M - - - - - - -

General and Administrative Expenses

83.6 M 76.6 M 76.5 M 75.2 M 73.7 M 70.9 M 70.7 M 60.5 M 75.6 M 65.5 M 61.8 M 57.6 M 55.6 M 49.1 M 56.3 M 53.2 M 53.6 M 54.6 M 54.3 M 52.1 M 48.4 M 44.3 M 39.1 M - 29.1 M 26.7 M 27.5 M 28.3 M 24.6 M 23.7 M 19 M 17.3 M 15.9 M 16.6 M 15.9 M 16.1 M 15 M 11.2 M 9.18 M 8.57 M 7.13 M 8.14 M 7.02 M 6.47 M 5.96 M 6.24 M 6.02 M 4.98 M 4.47 M 4.33 M 3.38 M 3.37 M 2.9 M 3.12 M 3.31 M 3.25 M 3.13 M 3.42 M 3.43 M 4.27 M 2.49 M 2.29 M 2.44 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Repligen Corporation RGEN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Repligen Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical instruments industry

Issuer Price % 24h Market Cap Country
Repro Med Systems Repro Med Systems
KRMD
$ 3.19 -7.41 % $ 147 M usaUSA
InfuSystem Holdings InfuSystem Holdings
INFU
$ 14.39 2.35 % $ 297 M usaUSA
electroCore electroCore
ECOR
$ 4.5 -7.22 % $ 38.2 M usaUSA
OraSure Technologies OraSure Technologies
OSUR
$ 3.48 -3.6 % $ 256 M usaUSA
iRhythm Technologies iRhythm Technologies
IRTC
$ 94.92 0.72 % $ 3.04 B usaUSA
ResMed ResMed
RMD
$ 235.13 -0.78 % $ 34.2 B usaUSA
Harvard Bioscience Harvard Bioscience
HBIO
$ 8.62 -0.69 % $ 383 M usaUSA
CRH Medical Corporation CRH Medical Corporation
CRHM
- - $ 282 M usaUSA
Retractable Technologies Retractable Technologies
RVP
$ 0.56 -6.53 % $ 16.8 M usaUSA
Microbot Medical Microbot Medical
MBOT
$ 0.68 -8.79 % $ 31.1 M israelIsrael
Haemonetics Corporation Haemonetics Corporation
HAE
$ 119.94 -0.3 % $ 5.66 B usaUSA
Cantel Medical Corp. Cantel Medical Corp.
CMD
- -1.18 % $ 3.4 B usaUSA
STERIS plc STERIS plc
STE
$ 255.68 0.31 % $ 25.1 B usaUSA
ICU Medical ICU Medical
ICUI
$ 172.0 -2.14 % $ 4.24 B usaUSA
Merit Medical Systems Merit Medical Systems
MMSI
$ 84.35 -0.07 % $ 4.99 B usaUSA
Nephros Nephros
NEPH
$ 2.72 -4.26 % $ 28.9 M usaUSA
Pro-Dex Pro-Dex
PDEX
$ 62.2 -2.03 % $ 201 B usaUSA
Envista Holdings Corporation Envista Holdings Corporation
NVST
$ 22.85 -1.63 % $ 3.84 B usaUSA
LeMaitre Vascular LeMaitre Vascular
LMAT
$ 73.73 -1.52 % $ 1.67 B usaUSA
Pulse Biosciences Pulse Biosciences
PLSE
$ 45.42 2.27 % $ 3.06 B usaUSA
Luminex Corporation Luminex Corporation
LMNX
- - $ 1.75 B usaUSA
STAAR Surgical Company STAAR Surgical Company
STAA
$ 24.2 -3.32 % $ 1.2 B usaUSA
Akers Biosciences, Inc. Akers Biosciences, Inc.
AKER
- -9.52 % $ 20.6 M usaUSA
Teleflex Incorporated Teleflex Incorporated
TFX
$ 161.56 -1.16 % $ 7.21 B usaUSA
Antares Pharma, Inc. Antares Pharma, Inc.
ATRS
- - $ 955 M usaUSA
Hill-Rom Holdings, Inc. Hill-Rom Holdings, Inc.
HRC
- -0.05 % $ 10.3 B usaUSA
Varian Medical Systems, Inc. Varian Medical Systems, Inc.
VAR
- -0.02 % $ 16.3 B usaUSA
DENTSPLY SIRONA DENTSPLY SIRONA
XRAY
$ 8.27 -2.65 % $ 1.65 B usaUSA
Ekso Bionics Holdings Ekso Bionics Holdings
EKSO
- - $ 28.6 M usaUSA
Isoray Isoray
ISR
- 0.03 % $ 108 M usaUSA
Masimo Corporation Masimo Corporation
MASI
- - $ 9.59 B usaUSA
Stereotaxis Stereotaxis
STXS
$ 0.95 -6.44 % $ 86.4 M usaUSA
Predictive Oncology Predictive Oncology
POAI
- - $ 31.1 M usaUSA
BioLife Solutions BioLife Solutions
BLFS
$ 38.61 3.51 % $ 1.84 B usaUSA
Utah Medical Products Utah Medical Products
UTMD
$ 70.46 -0.7 % $ 228 M usaUSA
West Pharmaceutical Services West Pharmaceutical Services
WST
$ 389.88 -1.72 % $ 28.2 B usaUSA
Baxter International Baxter International
BAX
$ 25.39 -0.02 % $ 13 B usaUSA
Glaukos Corporation Glaukos Corporation
GKOS
$ 236.75 -0.63 % $ 13.5 B usaUSA
Atrion Corporation Atrion Corporation
ATRI
- - $ 810 M usaUSA
Milestone Scientific Milestone Scientific
MLSS
$ 0.24 -0.83 % $ 19.7 M usaUSA
Alcon Alcon
ALC
$ 74.29 -0.32 % $ 36.6 B schweizSchweiz
AtriCure AtriCure
ATRC
$ 55.37 2.33 % $ 2.64 B usaUSA
NeuroMetrix NeuroMetrix
NURO
- 5.05 % $ 9.02 M usaUSA
Becton, Dickinson and Company Becton, Dickinson and Company
BDX
$ 212.18 -0.26 % $ 61 B usaUSA
AngioDynamics AngioDynamics
ANGO
$ 10.8 0.37 % $ 448 M usaUSA
The Cooper Companies The Cooper Companies
COO
$ 58.8 -2.54 % $ 11.7 B usaUSA
Intuitive Surgical Intuitive Surgical
ISRG
$ 400.35 -1.69 % $ 143 B usaUSA